// App-Quantinova.ai

2134 : Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program

Researchers

Presenter

  • Richard Warren

Principal Investigators

  • Howard Sofen

  • Shinichi Imafuku

  • Jacek C. Szepietowski

  • Andrew Blauvelt

  • Lynda Spelman

  • Jessica Toms

  • Alex Buck

  • Subhashis Banerjee

  • Alan Menter

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • UCLA School of Medicine, Los Angeles, CA

  • Fukuoka University Hospital, Fukuoka, Japan

  • Wroclaw Medical University, Wroclaw, Poland

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

  • Veracity Clinical Research, Woolloongabba, Australia

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol Myers Squibb; Cytel Inc, Princeton

  • Baylor University Medical Center, Dallas, TX

Locations

  • United Kingdom

  • United States

  • Japan

  • Poland

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

  • Dermatology

Disease

  • Psoriasis

  • Coronavirus disease

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03624127

  • NCT03611751

  • NCT04036435

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved